FDA Approves Belzutifan for Advanced Renal Cell Carcinoma
(MedPage Today) -- The FDA approved belzutifan (Welireg) for previously treated advanced renal cell carcinoma (RCC), the agency announced on Thursday.
Belzutifan is indicated for RCC patients with disease progression after a PD-1/L1 checkpoint...
Source: MedPage Today Public Health - Category: American Health Source Type: news